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Bedfordshire Vascular Unit, Bedford Hospital NHS Trust, Kempston Road, Bedford MK42 9DJ, United KingdomAlthough neck-related IFU for most devices is similar, this is
becoming a movable feast with newer devices that accept
shorter/hyperangulated/conical necks. Lee et al.1 look at
deployments of devices (exempliﬁed by demonstrative
graphics) outside the typical neck IFU of 15 mm length with
<60 angulation. The devices, among the Cook Zenith and
Gore Excluder, however, include the AneuRx, which (despite
the undisputed knowledge of the authors and notwith-
standing its role in device evolution about a decade ago2) is
now an archaic device that is still being used surprisingly,
despite concerns regarding integrity, narrow application
scope, high delayed rupture rates,3e5 and even an FDA
warning in April 2001.6 Furthermore, FDA approval for de-
vices to be used for short necks (Ovation; January 2013) and
neck angulations up to 90 (Aorﬁx; February 2013) relaxes
the relatively narrow IFU constraints that the authors have
been working within, and this highlights the evolution of
EVAR itself and regional variations in practice, both with
devices and procedure. The Nellix device, as the authors
know, offers similar potential.7
An issue raised by some is whether treating patients
outside IFUs represents an ethical challenge, and, although
higher graft-related adverse events were reported for the
AneuRx, events as a result of deployments outside of IFU
were not device-speciﬁc.8 Although disagreeing somewhat
with the ethical concerns given that there must be an
element of ﬂexibility in how we use devices (no one in their
right minds would use a standard device for 5 mm neck
length), I would agree that there is enough in the literature
to suggest moving away from the AneuRx altogether now.
As migration is an issue in this scenario, moving towards the
Cook Zenith makes sense, and, importantly, the re-emphasis
on ballooning the top (which is my standard practice) is
welcome.
Another signiﬁcant issue is that as screening programmes
pick up people with smaller aneurysms, it is much more
likely that they will have favourable necks and therefore the
need to deploy devices out of IFU will likely diminish once
screening becomes more widely established, which relates
conversely to this paper. Parallels from small AAA EVAR
trials9 also imply driving down the numbers of devices
deployed outside of IFU, potentially reducing the costDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.03.027
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http://dx.doi.org/10.1016/j.ejvs.2013.04.004associated with the recognised high re-intervention rate in
this scenario and, as an extension, perhaps even lower
numbers of fenestrated EVARs undertaken.
Thus, although most centres will typically have a ‘work-
horse’ device, and this study indicates that EVAR may be
undertaken in patients with unfavourable neck anatomy
(which is a boundary most advanced endovascular opera-
tors push even when discounting modern CHIMPS appli-
cations, exempliﬁed by Fig. 11), perhaps the choice of device
in the ﬁrst place is open to question. In particular, when the
non-IFU patients were largely treated with the Cook
Zenithdif applicable to the “adverse” scenario, why not use
it in the “friendly” scenario? Having said that, this is a real-
life presentation of their practice, including issues such as
patients lost to follow-up, and I agree this is the world we
live in, but then, we must also move on.REFERENCES
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